Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11059932rdf:typepubmed:Citationlld:pubmed
pubmed-article:11059932lifeskim:mentionsumls-concept:C0677948lld:lifeskim
pubmed-article:11059932lifeskim:mentionsumls-concept:C0026565lld:lifeskim
pubmed-article:11059932lifeskim:mentionsumls-concept:C1334459lld:lifeskim
pubmed-article:11059932lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:11059932lifeskim:mentionsumls-concept:C0004083lld:lifeskim
pubmed-article:11059932lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:11059932lifeskim:mentionsumls-concept:C0205262lld:lifeskim
pubmed-article:11059932lifeskim:mentionsumls-concept:C0127400lld:lifeskim
pubmed-article:11059932lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:11059932lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:11059932pubmed:issue9lld:pubmed
pubmed-article:11059932pubmed:dateCreated2001-1-24lld:pubmed
pubmed-article:11059932pubmed:abstractTextIn the absence of other metastatic disease, the presence of lymph node metastasis remains the most important determinant of survival in colorectal cancer (CRC). Cluster designation 44 variant 6 (CD44v6) over-expression is associated with worse outcome in all stages of CRC. The CD44v6 is believed to confer metastatic potential through its facilitation of migration, extravasation and proliferation, although the specific means by which it conveys an adverse prognosis in CRC is unknown. The aim of the present study was to determine if CD44v6 over-expression in Stage II CRC subjects was associated with the presence of lymph node micrometastases.lld:pubmed
pubmed-article:11059932pubmed:languageenglld:pubmed
pubmed-article:11059932pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11059932pubmed:citationSubsetIMlld:pubmed
pubmed-article:11059932pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11059932pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11059932pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11059932pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11059932pubmed:statusMEDLINElld:pubmed
pubmed-article:11059932pubmed:monthSeplld:pubmed
pubmed-article:11059932pubmed:issn0815-9319lld:pubmed
pubmed-article:11059932pubmed:authorpubmed-author:ClarkeGGlld:pubmed
pubmed-article:11059932pubmed:authorpubmed-author:RyanEElld:pubmed
pubmed-article:11059932pubmed:authorpubmed-author:CrownSSlld:pubmed
pubmed-article:11059932pubmed:authorpubmed-author:O'KeaneJ CJClld:pubmed
pubmed-article:11059932pubmed:authorpubmed-author:MathúnaP MPMlld:pubmed
pubmed-article:11059932pubmed:issnTypePrintlld:pubmed
pubmed-article:11059932pubmed:volume15lld:pubmed
pubmed-article:11059932pubmed:ownerNLMlld:pubmed
pubmed-article:11059932pubmed:authorsCompleteYlld:pubmed
pubmed-article:11059932pubmed:pagination1028-31lld:pubmed
pubmed-article:11059932pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11059932pubmed:meshHeadingpubmed-meshheading:11059932...lld:pubmed
pubmed-article:11059932pubmed:meshHeadingpubmed-meshheading:11059932...lld:pubmed
pubmed-article:11059932pubmed:meshHeadingpubmed-meshheading:11059932...lld:pubmed
pubmed-article:11059932pubmed:meshHeadingpubmed-meshheading:11059932...lld:pubmed
pubmed-article:11059932pubmed:meshHeadingpubmed-meshheading:11059932...lld:pubmed
pubmed-article:11059932pubmed:meshHeadingpubmed-meshheading:11059932...lld:pubmed
pubmed-article:11059932pubmed:meshHeadingpubmed-meshheading:11059932...lld:pubmed
pubmed-article:11059932pubmed:meshHeadingpubmed-meshheading:11059932...lld:pubmed
pubmed-article:11059932pubmed:meshHeadingpubmed-meshheading:11059932...lld:pubmed
pubmed-article:11059932pubmed:meshHeadingpubmed-meshheading:11059932...lld:pubmed
pubmed-article:11059932pubmed:meshHeadingpubmed-meshheading:11059932...lld:pubmed
pubmed-article:11059932pubmed:year2000lld:pubmed
pubmed-article:11059932pubmed:articleTitleMortality association of enhanced CD44v6 expression is not mediated through occult lymphatic spread in stage II colorectal cancer.lld:pubmed
pubmed-article:11059932pubmed:affiliationDepartment of Gastroenterology, Mater Misericordiae Hospital Dublin, Ireland. gclarke@rics.bwh.harvard.edulld:pubmed
pubmed-article:11059932pubmed:publicationTypeJournal Articlelld:pubmed